File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer

TitlePhase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer
Authors
Keywordscisplatin
palliative chemotherapy
nasopharyngeal cancer
distant metastases
capecitabine
Issue Date2012
Citation
Head and Neck, 2012, v. 34, n. 9, p. 1225-1230 How to Cite?
AbstractBackground Capecitabine is an oral fluoropyrimidine with single-agent activity in metastatic nasopharyngeal carcinoma (NPC). This multicenter phase II study was conducted to investigate the efficacy and safety of capecitabine plus cisplatin as a first-line treatment for metastatic NPC. Methods Patients with metastatic NPC received cisplatin 100 mg/m2 day 1 plus capecitabine 1000 mg/m2 twice daily on days 1 to 14 every 3 weeks for 6-8 cycles. The primary endpoint was overall response rate. Results Forty-four patients were enrolled; 39 patients were evaluable for efficacy. The overall response rate was 53.8% (95% confidence interval [CI], 37%-70%), including 1 complete response. Median time to tumor progression was 7.3 months (95% CI, 5.6-9.9 months) and median overall survival was 28.0 months (95% CI, 14.5 months-not reached). Common grade 3/4 adverse events were neutropenia (50%), vomiting (11%), thrombocytopenia (9%), and nausea (7%). Conclusions Capecitabine plus cisplatin is an active first-line combination in metastatic NPC that requires a short hospital stay. © 2011 Wiley Periodicals, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/282102
ISSN
2023 Impact Factor: 2.3
2023 SCImago Journal Rankings: 1.034
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChua, Daniel T.T.-
dc.contributor.authorYiu, Harry Ho Yin-
dc.contributor.authorSeetalarom, Kasan-
dc.contributor.authorNg, Alice Wan Ying-
dc.contributor.authorKurnianda, Johan-
dc.contributor.authorShotelersuk, Kanjana-
dc.contributor.authorKrishnan, Gopala-
dc.contributor.authorHong, Ruey Long-
dc.contributor.authorYang, Muh Hwa-
dc.contributor.authorWang, Cheng Hsu-
dc.contributor.authorSze, Wing Kin-
dc.contributor.authorNg, Wai Tong-
dc.date.accessioned2020-04-29T07:36:03Z-
dc.date.available2020-04-29T07:36:03Z-
dc.date.issued2012-
dc.identifier.citationHead and Neck, 2012, v. 34, n. 9, p. 1225-1230-
dc.identifier.issn1043-3074-
dc.identifier.urihttp://hdl.handle.net/10722/282102-
dc.description.abstractBackground Capecitabine is an oral fluoropyrimidine with single-agent activity in metastatic nasopharyngeal carcinoma (NPC). This multicenter phase II study was conducted to investigate the efficacy and safety of capecitabine plus cisplatin as a first-line treatment for metastatic NPC. Methods Patients with metastatic NPC received cisplatin 100 mg/m2 day 1 plus capecitabine 1000 mg/m2 twice daily on days 1 to 14 every 3 weeks for 6-8 cycles. The primary endpoint was overall response rate. Results Forty-four patients were enrolled; 39 patients were evaluable for efficacy. The overall response rate was 53.8% (95% confidence interval [CI], 37%-70%), including 1 complete response. Median time to tumor progression was 7.3 months (95% CI, 5.6-9.9 months) and median overall survival was 28.0 months (95% CI, 14.5 months-not reached). Common grade 3/4 adverse events were neutropenia (50%), vomiting (11%), thrombocytopenia (9%), and nausea (7%). Conclusions Capecitabine plus cisplatin is an active first-line combination in metastatic NPC that requires a short hospital stay. © 2011 Wiley Periodicals, Inc.-
dc.languageeng-
dc.relation.ispartofHead and Neck-
dc.subjectcisplatin-
dc.subjectpalliative chemotherapy-
dc.subjectnasopharyngeal cancer-
dc.subjectdistant metastases-
dc.subjectcapecitabine-
dc.titlePhase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/hed.21884-
dc.identifier.pmid22076785-
dc.identifier.scopuseid_2-s2.0-84864966763-
dc.identifier.volume34-
dc.identifier.issue9-
dc.identifier.spage1225-
dc.identifier.epage1230-
dc.identifier.eissn1097-0347-
dc.identifier.isiWOS:000307596000004-
dc.identifier.issnl1043-3074-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats